APUS (Apimeds Pharmaceuticals Us) Days Payable: 0.00 (As of Mar. 2026)


APUS Apimeds Pharmaceuticals Us Inc APUS
14 GF Score
Price $0.72
! 3 Warning Signs
View Full Analysis

What is Apimeds Pharmaceuticals Us Days Payable?

Apimeds Pharmaceuticals Us APUS -2.04% 14 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates APUS with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 927 Drug Manufacturers companies, Apimeds Pharmaceuticals Us ranks worse than 107874.76% on this metric.

Apimeds Pharmaceuticals Us's average Accounts Payable for the three months ended in Mar. 2026 was $0.92 Mil. Apimeds Pharmaceuticals Us's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil.

The historical rank and industry rank for Apimeds Pharmaceuticals Us's Days Payable or its related term are showing as below:

APUS's Days Payable is not ranked *
in the Drug Manufacturers industry.
Industry Median: 90.38
* Ranked among companies with meaningful Days Payable only.

Apimeds Pharmaceuticals Us's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Apimeds Pharmaceuticals Us Days Payable Historical Data

* Premium members only.

The historical data trend for Apimeds Pharmaceuticals Us's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apimeds Pharmaceuticals Us Days Payable Chart

Apimeds Pharmaceuticals Us Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Days Payable
0.00 0.00 0.00 0.00 0.00

Apimeds Pharmaceuticals Us Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

APUS vs KAYS, BIOE, BFRI: Days Payable Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Apimeds Pharmaceuticals Us's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apimeds Pharmaceuticals Us Days Payable vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apimeds Pharmaceuticals Us's Days Payable distribution charts can be found below:

* The bar in red indicates where Apimeds Pharmaceuticals Us's Days Payable falls into.


APUS
14GF Score
Apimeds Pharmaceuticals Us Inc APUS
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apimeds Pharmaceuticals Us Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Apimeds Pharmaceuticals Us's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

Days Payable (A: Dec. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2024 ) + Accounts Payable (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (0.591 + 0.919) / 2 ) / 0*365
=0.755 / 0*365
=N/A

Apimeds Pharmaceuticals Us's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

Days Payable (Q: Mar. 2026 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2025 ) + Accounts Payable (Q: Mar. 2026 )) / count ) / Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=( (0.919 + 0) / 1 ) / 0*365 / 4
=0.919 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Apimeds Pharmaceuticals Us (APUS) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Apimeds Pharmaceuticals Us and its competitors. According to the industry distribution chart, Apimeds Pharmaceuticals Us ranks #999999 out of 927 companies in the Drug Manufacturers industry.
Is Apimeds Pharmaceuticals Us' Days Payable too high?
Apimeds Pharmaceuticals Us' current Days Payable is 0.00. Based on the distribution chart, Apimeds Pharmaceuticals Us ranks #999999 out of 927 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Apimeds Pharmaceuticals Us' Days Payable compare to KAYS and BIOE?
According to the Drug Manufacturers industry distribution chart, Apimeds Pharmaceuticals Us ranks #999999 out of 927 companies for Days Payable. This places Apimeds Pharmaceuticals Us in the lower half of its industry. The industry median Days Payable is 90.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Apimeds Pharmaceuticals Us and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apimeds Pharmaceuticals Us's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apimeds Pharmaceuticals Us stock overvalued right now?
Apimeds Pharmaceuticals Us (APUS) has a current Days Payable of 0.00. The current Days Payable is 0.00. Apimeds Pharmaceuticals Us' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apimeds Pharmaceuticals Us Business Description

Address 100 Matawan Road, Suite 325, Matawan, NJ, USA, 07747
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
14GF Score

Get the complete analysis for APUS

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price